Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
All LSBio Custom kits have been predesigned and all necessary components, including antibodies and standards have been identified. Upon receiving a custom kit order, the kit will be assembled and quality control tested before being shipped out. Kit assembly and testing typically takes 4 to 6 weeks. In most cases the final kit is based on the Sandwich assay principle, with a few being Competitive EIA based. Specifications such as Range, Sensitivity, and Precision are defined upon completion. In the event that the custom kit cannot be successfully developed with 6 weeks of the order date, the customer will be notified and the order canceled at no cost.
LS-F14133 is a 96-well enzyme-linked immunosorbent assay (ELISA) for the detection of Human HMGB3. It is based upon a Custom assay principle.
HMGB3 ElisaKit, High mobility group protein 2a ElisaKit, High mobility group protein B3 ElisaKit, HMG-2a ElisaKit, High mobility group box 3 ElisaKit, High mobility group protein 4 ElisaKit, High-mobility group box 3 ElisaKit, HMG-4 ElisaKit, HMG2A ElisaKit, HMG4 ElisaKit
HMGB3 is a member of a family of proteins containing one or more high mobility group DNA-binding motifs. The encoded protein plays an important role in maintaining stem cell populations, and may be aberrantly expressed in tumor cells. A mutation in this gene was associated with microphthalmia, syndromic 13. There are numerous pseudogenes of this gene on multiple chromosomes. Alternative splicing results in multiple transcript variants.